yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q41874321-BAE0EE10-D0AB-4D0A-A267-BC907D5A1434
Q41874321-BAE0EE10-D0AB-4D0A-A267-BC907D5A1434
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41874321-BAE0EE10-D0AB-4D0A-A267-BC907D5A1434
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
P2860
Q41874321-BAE0EE10-D0AB-4D0A-A267-BC907D5A1434
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41874321-BAE0EE10-D0AB-4D0A-A267-BC907D5A1434
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b708d698648f4b088085aa803fdfd29d317a09ef
P2860
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.